The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Isoprenoids as mediators of the biological effects of statins
Open accessAbstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol biosynthesis.Several large clinical trials have demonstrated the benefits of cholesterol lowering with these agents in the primary and secondary prevention of coronary heart disease.The overall clinical benefits observed with statin therapy, however, appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels.Recent experimental and clinical evidence indicates that some of the cholesterol-independent, or so-called pleiotropic, effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response in the vascular wall.Many of these cholesterolindependent effects reflect statins' ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules.In particular, the inhibition of small GTP-binding proteins Rho, Ras, and Rac, whose proper membrane localization and function are dependent upon isoprenylation, may play an important role in mediating the biological effects of statins. Pharmacological properties of statinsStatins bind to HMG-CoA reductase at nanomolar concentrations, leading to competitive displacement of the natural substrate, HMG-CoA, which binds at micromolar concentrations (1).In addition, inhibition of cholesterol biosynthesis is accompanied by an increase in hepatic LDL receptor, which promotes uptake and clearance of cholesterol from the bloodstream.While all statins inhibit hepatic HMG-CoA reductase to varying degrees, important structural differences exist among the statins that distinguish their lipophilicity, half-life, and potency (2).For example, one of the more potent newer statins, rosuvastatin, is relatively hydrophilic and has a greater number of bonding interactions with the catalytic site of HMG-CoA reductase compared with mevastatin, fluvastatin, simvastatin, cerivastatin, and atorvastatin (1, 3).The lipophilic statins would be expected to penetrate cell membranes more effectively than the more hydrophilic statins, causing more side effects but, at the same time, eliciting more pleiotropic effects.However, the observation that hydrophilic statins have pleiotropic effects similar to those of lipophilic statins calls into question whether there are really any cholesterol-independent effects of statins.Indeed, recent evidence suggests that some of the cholesterol-independent effects of these agents may be mediated by inhibition of hepatic HMG-CoA reductase, leading to subsequent reduction in circulating isoprenoid levels (4).This hypothesis may help explain why hydrophilic statins such as pravastatin and rosuvastatin are still able to exert cholesterol-independent benefits on the vascular wall without directly entering vascular wall cells.In this respect, the word "pleiotropic" probably does not reflect the hepatic versus nonhepatic effects of these agents. Clinical trials with statinsBecause serum cholesterol level is strongly associated with coronary heart disease (5), it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects in cardiovascular diseases.However, subgroup analysis of large clinical trials such as the 4S, WOSCOP, CARE, and HPS suggests that the clinical benefits of statins are not associated with base-line cholesterol levels or the degree of cholesterol reduction (6-9).Furthermore, in angiographic trials, clinical improvements with statins far exceed changes in the size of atherosclerotic lesions (10).It is quite likely that cholesterol lowering in these longterm trials stabilized atherosclerotic plaques and made them less prone to rupture.However, in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, statins reduced recurrent ischemic events within 16 weeks following acute coronary ischemia (11).Although the serum LDL-cholesterol was decreased by 40%, this time frame was probably far too rapid for appreciable changes in lesion size and plaque stability to occur as a consequence of cholesterol reduction.An intriguing but perplexing result of large clinical trials with statins is the reduction in ischemic stroke ( 12).Although myocardial infarction is closely associated with serum cholesterol levels, neither the Framingham Heart Study nor the Multiple Risk Factor Intervention Isoprenoids as mediators of the biological effects of statins
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the effects of statins are connected with the inhibition of the synthesis of important isoprenoids, e.g.farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ subunit of heterotrimeric G-proteins [12] , guanosine triphosphatebinding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) [12][13][14] .”
From Statins as antifungal agents (2011) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Rho GTPases and signaling networksPreprint
Aelst, L. V., & D’Souza‐Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 201–300 of 355
Cutaneous melanoma: pathogenesis and rationale for chemoprevention
Demierre, M., & Sondak, V. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.11.001 · Cited by 25
Molecular Basis for Statin-Induced Muscle Toxicity: Implications and Possibilities
Buettner, C., & Lecker, S. H. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1133 · Cited by 25
Cheng, W., Ho, W., Chang, C., Lu, P., Cheng, P., Yeh, T., Hong, L., Sun, G., Hsiao, M., & Tseng, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12317 · Cited by 24
The analytical determination of isoprenoid intermediates from the mevalonate pathway
Nürenberg, G., & Volmer, D. A. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5262-2 · Cited by 24
Tang, Q., Huang, J., Qian, H., Chen, L., Wang, T., Wang, H., She, Z., Wu, H. B. K., & Xiong, R. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.11.045 · Cited by 24
Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2010) · Acta Biologica Hungarica · doi:10.1556/abiol.61.2010.3.11 · Cited by 23
Metabolism, LXR/LXR ligands, and tumor immune escape
Russo, V. E. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411198 · Cited by 26
Abeles, A. M., Marjanović, N., Park, J., Attur, M. G., Chan, E. S. L., Al-Mussawir, H., Dave, M. N., Fisher, M. C., Stuchin, S. A., Abramson, S. B., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22824 · Cited by 23
Huang, X., Ma, J., Xu, J., SU, Q., & Zhao, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2976 · Cited by 23
Hamasaki, Y., Doi, K., Okamoto, K., Ijichi, H., Seki, G., Maeda-Mamiya, R., Fujita, T., & Noiri, E. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.71 · Cited by 23
Shen, Y., Du, Y., Zhang, Y., & Pan, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3406 · Cited by 22
Łoboda, A., Stachurska, A., Dorosz, J., Zurawski, M., Węgrzyn, J., Kozakowska, M., Józkowicz, A., & Dulak, J. (2009) · Vascular Pharmacology · doi:10.1016/j.vph.2009.05.005 · Cited by 22
Jiang, B. H., Tardif, J., Sauvageau, S., Ducharme, A., Shi, Y., Martin, J. G., & Dupuis, J. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.03.003 · Cited by 22
Simon, M. S., Desai, P. M., Wallace, R. B., Wu, C., Howard, B. V., Martin, L. W., Schlecht, N. F., Liu, S., Jay, A. M., LeBlanc, E. S., et al. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0717-6 · Cited by 22
Statins and their potential targets in multiple sclerosis therapy
Stüve, O., Prod’homme, T., Slavin, A., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.5.613 · Cited by 22
Lozanoska‐Ochser, B., Barone, F., Pitzalis, C., & Peakman, M. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1261 · Cited by 22
Rye, M. B., Bertilsson, H., Andersen, M. K., Rise, K., Bathen, T. F., Drabløs, F., & Tessem, M.-B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4373-y · Cited by 21
Galgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21
Differential effects of simvastatin on membrane organization and dynamics in varying phases
Sahu, S. S., Sarkar, P., Shrivastava, S. K., & Chattopadhyay, A. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.104831 · Cited by 23
Pharmacological modulation of fibrinolytic response – In vivo and in vitro studies
Kramkowski, K., Leszczynska, A., & Buczko, W. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.022 · Cited by 21
Spectrum of Pleiotropic Effects of Statins in Heart Failure
Mathur, N., Ramasubbu, K., & Mann, D. L. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.01.007 · Cited by 21
Hamid, P. H., Hirzmann, J., Hermosilla, C. R., & Taubert, A. (2014) · Parasitology Research · doi:10.1007/s00436-014-4092-5 · Cited by 21
Gonzálvez, M., Ros, J. A. R., Pérez-Paredes, M., Lozano, M. L., Giménez, D. M., Martínez-Corbalán, F., Carnero, A., Cubero, T., Gómez, A. E., & Vicente, V. (2004) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60469-6 · Cited by 20
DOMANSKI, M. J., Tian, X., Fleg, J. L., Coady, S., Gosen, C., Kirby, R., Sachdev, V., Knatterud, G. L., & D, E. B. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.053 · Cited by 20
Ramasubbu, K., & Mann, D. L. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.031 · Cited by 20
Lee, S. H., Raboune, S., Walker, J. M., & Bradshaw, H. B. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11103965 · Cited by 20
Current questions regarding the use of statins in patients with coronary heart disease
Rallidis, L. S., Lekakis, J. P., & Kremastinos, D. T. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.12.030 · Cited by 19
Assessment of the in vitro and in vivo activity of atorvastatin against Candida albicans.
Ajdidi, A., Sheehan, G., Abu Elteen, K., & Kavanagh, K. (2019) · Journal of medical microbiology · doi:10.1099/jmm.0.001065 · Cited by 18
Eisa-Beygi, S., Ekker, M., Moon, T. W., Macdonald, R. L., & Wen, X. (2014) · Reproductive Toxicology · doi:10.1016/j.reprotox.2014.04.001 · Cited by 18
Carrascal, Y., Arnold, R. J., de la Fuente, L., Revilla, A., Sevilla, T., Arce, N., Laguna, G., Pareja, P., & Blanco, M. (2016) · Journal of Arrhythmia · doi:10.1016/j.joa.2016.01.010 · Cited by 18
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0123 · Cited by 19
Uličná, O., Vančová, O., Waczulı́ková, I., Božek, P., Šikurová, L., Bada, V., & Kucharská, J. (2012) · Physiological Research · doi:10.33549/physiolres.932236 · Cited by 18
Effect of pravastatin on the survival of patients with advanced gastric cancer
Bujanda, L., Rodríguez-González, A., Sarasqueta, C., Eizaguirre, E., Hijona, E., Marı́n, J. J. G., Perugorria, M. J., Bañales, J. M., & Cosme, Á. (2015) · Oncotarget · doi:10.18632/oncotarget.6777 · Cited by 18
Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems
Licărete, E., Sesărman, A., & Banciu, M. (2015) · Journal of Microencapsulation · doi:10.3109/02652048.2015.1073383 · Cited by 16
Egom, E. E. A., Rose, R. A., Neyses, L., Soran, H., Cleland, J. G. F., & Mamas, M. A. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.813013 · Cited by 17
Yang, Y., Rong, X., Lv, X., Jiang, W., Yang, Y., Lai, D., Xu, S., & Fu, G. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12285 · Cited by 17
Inhibition of Rho modulates cytokine-induced prostaglandin E2 formation in renal mesangial cells
Nold‐Petry, C. A., Fritz, G., Pfeilschifter, J. M., & Huwiler, A. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2003.11.007 · Cited by 17
Sugimoto, H., Iguchi, M., & Jinno, F. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0293-y · Cited by 16
Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies
Dubińska–Magiera, M., Migocka-Patrzałek, M., Lewandowski, D., Daczewska, M., & Jagla, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115654 · Cited by 17
Mariucci, G., Taha, E., Tantucci, M., Spaccatini, C., Tozzi, A., & Ambrosini, M. V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.002 · Cited by 15
Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study
Chitnis, A. S., Aparasu, R. R., Chen, H., Kunik, M. E., Schulz, P. E., & Johnson, M. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0295-4 · Cited by 15
Kobori, T., Kobayashi, M., Harada, S., Nakamoto, K., Fujita‐Hamabe, W., & Tokuyama, S. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.08.019 · Cited by 15
Hamilton, P., Hughes, S., Plumb, R. D., Devine, A. B., Leahey, W. J., Lyons, K., Johnston, D., & McVeigh, G. E. (2009) · Clinical Science · doi:10.1042/cs20090388 · Cited by 15
Dose-dependency in pleiotropic effects of atorvastatin
Fujita, M., Morimoto, T., Ikemoto, M., Takeda, M., Ikai, A., & Miwa, K. (2007) · International Journal of Angiology · doi:10.1055/s-0031-1278256 · Cited by 15
Statins and transcriptional regulation: The FXR connection
Habeos, I. G., Ziros, P. G., Psyrogiannis, A. I., Vagenakis, A. G., & Papavassiliou, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.129 · Cited by 15
Emerging therapies for pulmonary arterial hypertension
Ali, O., Wharton, J., Gibbs, J., Howard, L., & Wilkins, M. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.803 · Cited by 15
In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes
Galgóczy, L., Papp, T., & Vágvölgyi, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01634.x · Cited by 14
Postolache, T. T., Medoff, D. R., Brown, C. H., Fang, L., Upadhyaya, S. K., Lowry, C. A., Miller, M. J., & Kreyenbuhl, J. A. (2021) · Pteridines · doi:10.1515/pteridines-2020-0028 · Cited by 12
Şaman, E., Cebová, M., Barta, A., Koneracká, M., Závišová, V., Andicsová, A. E., Danko, M., Mosnáček, J., & Pecháňová, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010276 · Cited by 14
Control de las hiperlipemias en la práctica clínica
Rodrigo Alonso, K., Pariente, N. M., & López, P. M. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)75326-2 · Cited by 14
Jaśkiewicz, A., Pająk, B., Łabieniec-Watała, M., Palma, C. D., & Orzechowski, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050694 · Cited by 13
Statins and the Response to Myocardial Injury
Scalia, R. G. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00003 · Cited by 14
Statins as potential therapeutic agents in multiple sclerosis
Stüve, O., Prod’homme, T., Youssef, S., Dunn, S. E., Neuhaus, O., Weber, M. S., Hartung, H.-P., Steinman, L., & Zamvil, S. S. (2004) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-004-0044-2 · Cited by 14
Dai, B., Liu, X., Du, M., Xie, S., Dou, L., Mi, X., Zhou, D., Su, Y., Shen, T., Zhang, Y., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.07.019 · Cited by 13
Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation
Zheng, E., Warchoł, I., Mejza, M., Możdżan, M., Strzemińska, M., Bajer, A., Madura, P., Żak, J., & Plewka, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030882 · Cited by 17
Schelz, Z., Muddather, H. F., & Zupkó, I. (2023) · Antibiotics · doi:10.3390/antibiotics12091468 · Cited by 14
Long‐term diabetic complications may be ameliorated by targeting Rho kinase
Zhou, H., & Li, Y. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1182 · Cited by 13
Modulation of heat shock proteins by statins
Forouzanfar, F., Butler, A. E., Banach, M., Barreto, G. E., & Sahbekar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.020 · Cited by 13
Microparticles in type 2 diabetes mellitus
Davı̀, G., & Ferroni, P. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01196.x · Cited by 13
Fitzgerald, J. P., Chou, S., Franco, I., Mooppan, U. M. M., Kim, H., Saini, R., & Gulmi, F. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.04.086 · Cited by 13
Kamal, A., Boerner, J. L., Assad, H., Chen, W., & Simon, M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179587 · Cited by 15
Successful treatment of xanthoma disseminatum with simvastatin
Lee, E. H., Tae Won, K. A. N. G., & Kim, S. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2011.01201.x · Cited by 12
Novel effects of statins in enhancing efficacy of chemotherapy in vitro in nasopharyngeal carcinoma
Wang, W., Le, W., Cho, D., Hwang, P. H., & Upadhyay, D. (2011) · International Forum of Allergy & Rhinology · doi:10.1002/alr.20039 · Cited by 12
Ames, P. R. J., Ortiz-Cadenas, A., Torre, I. G.-D. L., Nava, A., Oregon-Miranda, A., Batuca, J. R., Kojima, K., Lopez, L. R., & Matsuura, E. (2010) · The British Journal of Diabetes · doi:10.1177/1474651410388057 · Cited by 12
Cui, H., Soga, K., Tamehiro, N., Adachi, R., Hachisuka, A., Hirose, A., Kondo, K., & Nishimaki‐Mogami, T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114580 · Cited by 12
Cardioprotective and other emerging effects of statins
Davignon, J. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00391.x · Cited by 12
Contrast-Induced Acute Kidney Injury
McCullough, P. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00048-0 · Cited by 12
Ataga, K. I., Wichlan, D., Elsherif, L., Derebail, V. K., Wogu, A. F., Maitra, P., Cai, J., Caughey, M. C., Pollock, D. M., Pollock, J. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25614 · Cited by 11
Inactivation of Rho GTPases by Statins Attenuates Anthrax Lethal Toxin Activity
deCathelineau, A. M., & Bokoch, G. (2008) · Infection and Immunity · doi:10.1128/iai.01005-08 · Cited by 11
A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast
Takami, T., Fang, Y., Zhou, X., Jaiseng, W., Ma, Y., & Kuno, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049004 · Cited by 11
Pappu, A. S., Connor, W. E., Merkens, L. S., Jordan, J. M., Penfield, J. A., Illingworth, D. R., & Steiner, R. D. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600295-jlr200 · Cited by 11
Pascapurnama, D. N., Labayo, H. K. M., Dapat, I. C., Nagarajegowda, D. D., Zhao, J., Zhang, J., Yamada, O., Kikuchi, H., Egawa, S., Oshima, Y., et al. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00521 · Cited by 11
Bews, H. J., Carlson, J. C., Jha, A., Basu, S., Halayko, A. J., & Wong, C. S. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.12.030 · Cited by 10
Talbot, D. C., Delaney, J. A., Sandfort, V., Herrington, D. M., & McClelland, R. L. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4393 · Cited by 10
Liang, Y., Sun, C., Hsu, Y.-C., Chen, Y., Wang, I.-A., Su, C., Tao, M., & Wu, J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00659-6 · Cited by 11
Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation
Voss, L., Guttek, K., Reddig, A., Reinhold, A., Voß, M., Simeoni, L., Schraven, B. L., & Reinhold, D. (2021) · Pharmaceuticals · doi:10.3390/ph14080727 · Cited by 12
Ray, K. K., & Cannon, C. P. (2005) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000154979.98731.5d · Cited by 10
Modeling cholesterol metabolism by gene expression profiling in the hippocampus
Valdez, C. M., Phelix, C. F., Smith, M. A., Perry, G. L., & Santamarı́a, F. (2011) · Molecular BioSystems · doi:10.1039/c0mb00282h · Cited by 11
Chantzichristos, V. G., Agouridis, A. P., Moutzouri, E., Stellos, K., Elisaf, M., & Tselepis, A. D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.047 · Cited by 11
Gonzálvez, M., Ros, J. A. R., Pérez-Paredes, M., Lozano, M. L., Giméneza, D. M., Martínez-Corbalán, F., Carnero, A., Cubero, T., Gómez, A. E., & Vicente, V. (2004) · Revista Española de Cardiología · doi:10.1016/s0300-8932(04)77219-x · Cited by 10
Re-endothelialization Via Bone Marrow-Derived Progenitor Cells
Thyberg, J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036415.04486.01 · Cited by 10
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells
Rezkallah, C. A. N., Thongkum, A., Zhu, C., & Chen, Q. M. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22484 · Cited by 9
The Role of Statins in the Prevention of Ovarian and Endometrial Cancers
Zeleznik, O. A., Irvin, S., Samimi, G., & Trabert, B. L. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0374 · Cited by 9
Yazdanpanah, M., Yazdanpanah, N., Chardoli, M., & Dehghan, A. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131964 · Cited by 9
Jung, Y. S., Oh, A., Park, H., Hwang, J., Lim, Y., & Jeon, Y.-T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.038 · Cited by 9
Desai, P. M., Wallace, R. B., Anderson, M. L., Howard, B. V., Ray, R. M., Wu, C., Safford, M. M., Martin, L. W., Schlecht, N. F., Liu, S., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1368 · Cited by 9
Pathophysiology of Contrast Induced Acute Kidney Injury
Madariaga, H. M., Stalam, T., Patel, A. M., & Thomas, B. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45414-2_12 · Cited by 9
The Role of Statins in the Prevention of Heart Failure After Acute Coronary Syndrome
Kumar, A., & Cannon, C. P. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.01.010 · Cited by 9
Yang, Y., Lu, X., Rong, X., Jiang, W., Lai, D., Ma, Y., Zhou, K., Fu, G., & Xu, S. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.01.010 · Cited by 9
Statine zur Behandlung von Erkrankungen des zentralen Nervensystems
Menge, T., von Büdingen, H. ‐., Zamvil, S. S., Hartung, H., Kieseier, B. C., & Stüve, O. (2004) · Der Nervenarzt · doi:10.1007/s00115-004-1806-4 · Cited by 9
Impact of Lipid Apheresis on Egr‐1, c‐Jun, c‐Fos, and Hsp70 Gene Expression in White Blood Cells
Schettler, V. J. J., Völker, K., Schulz, E. G., & Wieland, E. (2010) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2010.00861.x · Cited by 8
Simvastatin inhibits angiotensin II‐induced cardiac cell hypertrophy: Role of Homer 1a
Guo, W., Su, F., Yuan, L., Yang, G., Shi, X., Li, R., Shu, Q., Liu, X., Lu, Z., & Zheng, Q. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05221.x · Cited by 8
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
Lee, J., Kim, M. S., Ju, J. E., Lee, M., Chung, N., & Jeong, Y. K. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4192 · Cited by 8
Allah, E. A., Kamel, E. Z., Osman, H. M., Abd‐Elshafy, S. K., Nabil, F., ElMelegy, T. T. H., Elkhayat, H., Ibrahim, A. S., & Elminshawy, A. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.05.013 · Cited by 7
Do statins play a role in the early management of the acute coronary syndrome?
Sacks, F. M. (2004) · European Heart Journal Supplements · doi:10.1016/j.ehjsup.2004.01.008 · Cited by 7
Bucci, T., Menichelli, D., Palumbo, I., Pastori, D., Ames, P. R. J., Lip, G. Y. H., & Pignatelli, P. (2025) · Cells · doi:10.3390/cells14050353 · Cited by 8
Muller, K. S., Tibúrcio, F. C., de Barros, J. W. F., Matsumura, C. Y., & Matheus, S. M. M. (2023) · Muscle & Nerve · doi:10.1002/mus.27825 · Cited by 6
Lipid Interventions in Aortic Valvular Disease
Choi, K. J., Tsomidou, C., Lerakis, S., Madanieh, R., Vittorio, T. J., & Kosmas, C. E. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000544 · Cited by 6
Dick, M., MacDonald, K. N., Tardif, J., & Leask, R. L. (2015) · BioMedical Engineering OnLine · doi:10.1186/s12938-015-0057-x · Cited by 6
Metadata
- Authors
- Liao, J. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Liao, James K.
- ORCID
- Liao, James K.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-01
- Volume
- 110
- Issue
- 3
- Pages
- 285-288
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4235797558
- Cited by
- 352
- References
- 35
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 16 · 2013: 13 · 2012: 16
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, terpenoids, pleiotropy, cholesterol-independent effects, HMG-CoA reductase inhibition, cholesterol biosynthesis, isoprenylation, small GTPases, Rho, Ras, Rac, endothelial function, atherosclerotic plaque stability, oxidative stress, inflammation, thrombogenicity, statin adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
